Exenatide-Induced Acute Pancreatitis

Ayoub, Walaa A.; Kumar, Ashok; Naguib, Hossam S.; Taylor, Harris C.

doi:10.4158/ep09104.crr

Cited by 52 publications

(38 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increased risk of pancreatitis with incretin therapy was shown in some (4), but not all (8,9) experimental animal studies. In humans, a signal of pancreatitis associated with incretin use was detected by adverse event reports (10)(11)(12). However, spontaneous reports may be partially driven by professional and lay publications, while type 2 diabetes per se may increase the risk of acute pancreatitis 1.5-fold to 2-fold (13)(14)(15)(16)(17)(18).…”

mentioning

confidence: 99%

Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study

et al. 2015

View full text Add to dashboard Cite

OBJECTIVETo investigate whether the use of incretin-based drugs (GLP-1 receptor agonists and dipeptidyl peptidase 4 [DPP4] inhibitors) is associated with acute pancreatitis. RESEARCH DESIGN AND METHODSThe study was a nationwide population-based case-control study using medical databases in Denmark. Participants were 12,868 patients with a first-time hospitalization for acute pancreatitis between 2005 and 2012 and a population of 128,680 matched control subjects. The main outcome measure was the odds ratio (OR) for acute pancreatitis associated with different antihyperglycemic drugs. We adjusted for history of gallstones, alcoholism, obesity, and other pancreatitisassociated comorbidities and medications. RESULTSA total of 89 pancreatitis patients (0.69%) and 684 control subjects (0.53%) were ever users of incretins. The crude OR for acute pancreatitis among incretin users was 1.36 (95% CI 1.08-1.69), while it was 1.44 (95% CI 1.34-1.54) among users of other antihyperglycemic drugs. After confounder adjustment, the risk of acute pancreatitis was not increased among incretin users (OR 0.95 , compared with nonusers of any antihyperglycemic drugs. Findings were similar in current versus ever drug users and in patients with pancreatitis risk factors. The adjusted OR comparing incretinbased therapy with other antihyperglycemic therapy internally while also adjusting for diabetes duration and complications was 0.97 (95% CI 0.76-1.23). CONCLUSIONSOur findings suggest that the use of incretin-based drugs appears not to be associated with an increased risk of acute pancreatitis.Incretin-based therapies represent a new and widely used class of oral antihyperglycemic drugs for the treatment of type 2 diabetes (1). These agents currently include three injectable incretin mimetic agents (GLP-1 receptor agonists: exenatide, liraglutide, and lixisenatide), five incretin enhancers (dipeptidyl peptidase 4 [DPP4] inhibitors: sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin [not currently licensed in Denmark]), and combinations of these DPP4 inhibitors with metformin or

show abstract

mentioning

confidence: 99%

Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The microbial components in Yak yogurt have a large difference from general lactic acid because of the special working environment and fermentation [3]. Yak yogurt contains a large amount of Lactobacillus so that the deep separation and identification can isolate a high-quality Lactobacillus with probiotics potential [4,5].…”

Section: Introductionmentioning

confidence: 99%

Colitis reducing effects of Lactobacillus plantarum YS-4 in dextran sulfate sodium-induced C57BL/6J mice

Li¹,

Long²,

Pan³

et al. 2018

biomedicalresearch

View full text Add to dashboard Cite

show abstract

“…Although Ex-4 is generally well tolerated, post-marketing cases reported possible Ex-4-associated acute pancreatitis [3][4][5][6]. Analyses of the FDA Adverse Event Reporting System database and health insurance data have raised concerns about a potential increase in pancreatitis with use of GLP-1RAs based therapies [7,8].…”

Section: Introductionmentioning

confidence: 99%

Exendin-4 dose not evoke pancreatitis or pancreatitis-associated histopathological and genetic changes in high-fat diet induced diabetic mice

Sun¹,

Guo²,

Li³

et al. 2018

biomedicalresearch

View full text Add to dashboard Cite

Exenatide-Induced Acute Pancreatitis

Cited by 52 publications

References 11 publications

Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study

Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study

Colitis reducing effects of Lactobacillus plantarum YS-4 in dextran sulfate sodium-induced C57BL/6J mice

Exendin-4 dose not evoke pancreatitis or pancreatitis-associated histopathological and genetic changes in high-fat diet induced diabetic mice

Contact Info

Product

Resources

About